The Peptide Promise With NervGen's Mike Kelly

Business Of Biotech

We love to hear from our listeners. Send us a message.

Mike Kelly faced a self-reckoning before he took the job as CEO at NervGen, a company developing peptide therapeutics targeted specifically at central nervous system repair. The veteran of life sciences business development knew the ropes of the biotech C-suite. He’d been a CEO twice before. He knew how to launch drugs, having seen commercial success several times before. He even knew how to sell them—he’d started his career carrying the bag for TAP Pharmaceuticals. But all he knew about peptides was that they were challenging to manufacture consistently and purify. And he knew that manufacturing is where a lot of biopharma companies fall down. On this episode of the Business of Biotech, we learn how Kelly reconciled that truth, and how NervGen is now leading the way for peptide therapeutics in spinal cord injury and beyond.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

บท

1. The Peptide Promise With NervGen's Mike Kelly (00:00:00)

2. Exploring Therapeutic Peptides in Biotech (00:00:04)

3. Navigating Commercial Success in Pharma (00:11:15)

4. Leveraging People for Business Success (00:24:00)

5. Exploring Peptide Therapeutics in Neurology (00:29:40)

6. Peptides in Neuro Therapeutics Development (00:35:36)

7. Hiring Strategies for Startups (00:44:48)